MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

March 2023:

Brief Summary:

The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has come back or stopped responding to other treatments.

Detailed Description:

Primary Objectives

To determine the feasibility and safety of anti-MESO CAR-T cells in treating patients with MESO-positive ovarian cancer.

Secondary Objectives

To assess the efficacy of anti-MESO CAR-T cells in patients with ovarian cancer.

To determine the in vivo dynamics and persistency of anti-MESO CAR-T cells.

Study design

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Effectiveness of MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Estimated Study Start Date : April 20, 2019
Estimated Primary Completion Date : April 20, 2022
Estimated Study Completion Date : April 20, 2023

Criteria

Inclusion Criteria:

18 to 70 Years Old, female; Expected survival > 12 weeks; Clinical performance status of ECOG score 0–2; Patients who have previously been treated with second-line or more lines of standard treatment are not effective (No remission or recurrence after remission); At least one measurable tumor foci according to RECIST standard 1.1 ; Positive Mesothelin expression in tumor tissues; Creatinine ≤ 1.5×ULN; ALT and AST ≤ 3×ULN; Total bilirubin ≤ 2×ULN; Hemoglobin≥90g/L; Absolute counting of neutrophils≥1000uL ; Absolute counting of lymphocytes>0.7×10^9/L; Counting of Platelets≥75000/uL; The venous access required for collection can be established without contraindications for leukocyte collection. I am able to understand and sign the informed consent document.

Exclusion Criteria:

Accompanied by other uncontrolled malignant tumors; Active hepatitis B, hepatitis C, syphilis, HIV infection; Suffering severe cardiovascular or respiratory disease; Any other diseases could affect the outcome of this trial. Any affairs that could affect the safety of the subjects or outcome of this trial Pregnant or lactating women, or patients who plan to be pregnant during or after treatment; There are active or uncontrollable infections (except simple urinary tract infections or upper respiratory tract infections) that require systemic therapy 14 days or 14 days prior to assignment; Patients who are accounted by researchers as not appropriate for this test; Received CAR-T treatment or other gene therapies before assignment; Subject suffering disease affects the understanding of informed consent or compliance with study protocol.

Check the list of hospitals doing CAR T-Cell therapy in China.

Nishant Mittal (PhD)

+ postsBio ⮌

Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. His career is marked by significant contributions to stem cell biology, developmental biology, and innovative research techniques.

Research Highlights

Dr. Mittal's research has focused on several key areas:

1) Cardiovascular Development and Regeneration: He studied coronary vessel development and regeneration using zebrafish models1.

2) Cancer Biology: At Dartmouth College, he developed zebrafish models for studying tumor heterogeneity and clonal evolution in pancreatic cancer.
3) Developmental Biology: His doctoral work at Keio University involved identifying and characterizing medaka fish mutants with cardiovascular defects.

4) Stem Cell Research: He investigated the effects of folic acid on mouse embryonic stem cells and worked on cryopreservation techniques for hematopoietic stem cells.

Publications and Presentations

Dr. Mittal has authored several peer-reviewed publications in reputable journals such as Scientific Reports, Cardiovascular Research, and Disease Models & Mechanisms1. He has also presented his research at numerous international conferences, including the Stanford-Weill Cornell Cardiovascular Research Symposium and the Weinstein Cardiovascular Development Conference.

In summary, Dr. Nishant Mittal is a dedicated and accomplished researcher with a strong track record in cardiovascular and cancer biology, demonstrating expertise in various model systems and a commitment to advancing scientific knowledge through innovative research approaches.

• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Tafasitamab-cxix is approved by the USFDA for relapsed or refractory follicular lymphoma
• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Breakthrough Treatments for Advanced Breast Cancer in 2025
• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Mitomycin intravesical solution is approved by the USFDA for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Darolutamide is approved by the USFDA for metastatic castration-sensitive prostate cancer

• Comments Closed
• March 17th, 2023